CytomX Therapeutics appointed Charles Fuchs to its board of directors.
Fuchs most recently served as chief medical officer at Tubulis, overseeing clinical strategy and pipeline development.
He previously led oncology and hematology drug development at Genentech and Roche, advancing multiple therapies through approval.
CytomX flagged Fuchs’ gastrointestinal oncology experience as relevant to Varseta-M, its EpCAM-targeted ADC in development for metastatic colorectal cancer.
CTMX•
